2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2276 Cumulative infection burden predicts inferior survival during BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma

Ariel Siegel, MD, Karni Bedirian2, Ariel A Aptekmann, PhD3, Ramy Mahmoud4, Keyi Wang, PhD5, Erin Moshier, PhD6, Adolfo Aleman, PhD7, Cesar Rodriguez Valdes, MD8
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Icahn School of Medicine at Mount Sinai, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, New York, United States
6 Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 Icahn School of Medicine at Mount Sinai, New York, New York, United States
8 Icahn School of Medicine at Mount Sinai, New York, New York, United States

Introduction
Bispecific antibodies (BiAb) have established a new standard of care in relapsed/refractory multiple myeloma (RRMM), inducing deep and durable responses. However, sustained T cell engagement and on-target, off-tumor killing produce broad immune impairment, and infections remain a leading cause of morbidity. Whether cumulative infection burden is itself prognostic, rather than merely a toxicity, has not been formally examined. We hypothesized that cumulative infection burden during BCMA BiAb therapy reflects the same immune dysfunction that limits durable response and negatively impacts survival.

Methods
We conducted a retrospective single-center analysis of BCMA BiAb-treated RRMM patients. Baseline characteristics and the timing, type and CTCAE grade of infections were collected. Cumulative infection burden was analyzed separately for all-grade and high-grade (CTCAE ≥3) infections, modeled as a time-dependent linear exposure (primary analysis) and via restricted cubic splines (exploratory analysis). Multivariable Cox proportional hazards models were used to evaluate associations with PFS and OS, adjusting for high-risk cytogenetics, EMD, number of prior lines of therapy (LOT), baseline ALC, prior ASCT, prior CAR-T and cumulative BiAb doses in the first 90 days (to address dose-holding as a potential confounder; modeled linearly or as a restricted cubic spline based on non-linearity testing). Further analyses separated infection burden into early (≤90 days) and late (>90 days) exposure, and included a 90-day landmark sensitivity analysis. Patients were followed from BiAb initiation for up to 3 years.

Results
Among 117 patients with RRMM (49% HR cytogenetics, 21% EMD, median 5 prior LOT), 62 PFS events and 36 deaths were observed. 235 infections were documented in 90 patients (77%), with a median time to first infection of 85 days (95% CI 54-168); 220 occurring prior to progression were included in the PFS analysis. Infections were predominantly viral (49%) and bacterial (47%), while fungal infections were rare (3%). Cumulative all-grade infection burden was independently associated with inferior PFS (adjusted HR 1.24 per +1 infection, 95% CI 1.09-1.42, p=0.001), with a more pronounced effect for high-grade infections (adjusted HR 1.43, 95% CI 1.17-1.75, p<0.001). Both associations persisted after adjustment for cumulative BiAb doses in the first 90 days, arguing against dose interruptions being the primary driver. Exploratory spline analysis showed no significant deviation from linearity (p=0.088 for high-grade), but suggested the greatest relative hazard increase occurred between 0 and 1 high-grade infections (HR 2.49, 95% CI 1.28-4.83, p=0.007), with attenuated effects thereafter. Cumulative infection burden was similarly associated with inferior OS (all-grade HR 1.37, 95% CI 1.17-1.60; high-grade HR 1.71, 95% CI 1.39-2.09; both p<0.001). When classified by timing, early (≤90 days) cumulative infection burden was independently associated with inferior PFS (all-grade HR 1.37, 95% CI 1.14-1.64; high-grade HR 1.54, 95% CI 1.21-1.97; both p<0.001), while late (>90 days) infections were not significantly associated. In an exploratory 90-day landmark analysis (n=86), early any grade infection burden remained associated with inferior OS (HR 1.38, 95% CI 1.02-1.87, p=0.038), while the high-grade PFS landmark analysis was directionally consistent but not significant (HR 1.38, 95% CI 0.93-2.03, p=0.107).

Discussion
Cumulative infection burden during BCMA BiAb therapy is independently associated with inferior PFS and OS, persisting even after adjustment for early treatment intensity, which argues against dose interruption as the primary driver of impact. This prognostic signal is concentrated in infections occurring during the first 90 days, with the greatest relative hazard increase following the first high-grade infection. As the same T cell engagement that mediates anti-MM efficacy also drives immune impairment, the ability to avoid infection may reflect the integrity of the same immune compartments required for durable disease control. These findings reframe infections as dynamic clinical surrogates of immune dysfunction, rather than mere toxicities, and identify the early treatment window as a critical period for risk stratification and infection prevention. Studies characterizing immunophenotype and T cell function to identify the biological correlates of infection-associated immune dysfunction are underway.

Ariel Siegel, MD: No relevant conflicts of interest to declare.